NF-κb inhibitors

Details NF-κb inhibitors NF-κb inhibitors

2007-11-27

2007-11-27

Shameem, Golam M. M. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C549S029000, C549S041000, C549S049000, C549S057000, C514S438000, C514S443000

Reexamination Certificate

active

10517111

ABSTRACT:
The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-β phosphorylation of IκB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-κB in which diseases excessive activation of NF-κB is implicated.

REFERENCES:
patent: 4782080 (1988-11-01), Witzel
patent: 6018056 (2000-01-01), Schmid et al.
patent: 0 747 052 (1996-12-01), None
patent: WO 02/30353 (2002-04-01), None
Modica et al., “[[(Arylpiperazinyl)alkyl]thio]thieno[2,3-d]pyrimidinone Derivatives as High Affinity, Selective 5-HT1AReceptor Ligands”.J. Med. Chem., 40: 574-585 (1997).
Gewald et al., “2-Amino-thionaphthene”.Chemische Berichte, 101: 1933-1939 (1968).

Affiliated with

Also associated with

Rating

NF-κb inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with NF-κb inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and NF-κb inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3808922